Trial Profile
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sildenafil (Primary)
- Indications Chronic heart failure; Diastolic heart failure; Heart failure
- Focus Therapeutic Use
- Acronyms RELAX
- 17 Nov 2020 Results (n=122) assessing immunohematologic failure identifies fibrotic phenotype in heart failure with preserved ejection fraction, presented at the American Heart Association Scientific Sessions 2020
- 13 May 2020 Results published in the American Journal of Medicine
- 16 Mar 2020 Results of post-hoc analysis assessing characterization of the clinical, physiologic, and imaging-related phenotypic differences between HFpEF patients with and without anemia, published in the American Journal of Cardiology.